Edwards Lifesciences Corp (EW)vsInMode Ltd (INMD)
EW
Edwards Lifesciences Corp
$91.78
+1.06%
HEALTHCARE · Cap: $49.92B
INMD
InMode Ltd
$13.37
-1.55%
HEALTHCARE · Cap: $808.50M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 1638% more annual revenue ($6.51B vs $374.63M). INMD leads profitability with a 20.7% profit margin vs 15.4%. EW appears more attractively valued with a PEG of 1.85. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
INMD
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.5%
Fair Value
$251.45
Current Price
$91.78
$159.67 discount
Margin of Safety
+58.8%
Fair Value
$34.60
Current Price
$13.37
$21.23 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 21 of every $100 in revenue as profit
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
0.0% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : INMD
The strongest argument for INMD centers on P/E Ratio, Price/Book, Debt/Equity. Profitability is solid with margins at 20.7% and operating margin at 12.8%.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.5x leaves little room for execution misses.
Bear Case : INMD
The primary concerns for INMD are Revenue Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
EW profiles as a mature stock while INMD is a value play — different risk/reward profiles.
INMD carries more volatility with a beta of 2.03 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 52/100), backed by strong 15.4% margins and 13.6% revenue growth. INMD offers better value entry with a 58.8% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →InMode Ltd
HEALTHCARE · MEDICAL DEVICES · USA
InMode Ltd. designs, develops, manufactures and markets minimally invasive aesthetic medical products based on its proprietary RF-assisted lipolysis and deep subdermal fractional RF technologies. The company is headquartered in Yokneam, Israel.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?